Associate Professor of Obstetrics, Gynecology and Reproductive Biology
Markt SC, Tang T, Cronin AM, Katz IT, Howitt BE, Horowitz NS, Lee LJ, Wright AA
Insurance status and cancer treatment mediate the association between race/ethnicity and cervical cancer survival. PLoS One. 2018; 13(2):e0193047.
Insurance status and cancer treatment mediate the association between race/ethnicity and cervical cancer survival.
Horowitz NS, Tamimi HK, Goff BA, Koh WJ, Schmidt RA, Greer BE, Paley PJ
Pretreatment scalene node biopsy in gynecologic malignancy: prudent or passé? Gynecol Oncol. 1999 Nov; 75(2):238-41.
Pretreatment scalene node biopsy in gynecologic malignancy: prudent or passé?
Padrón L, Rezende Filho J, Amim Junior J, Sun SY, Charry RC, Maestá I, Elias KM, Horowitz N, Braga A, Berkowitz RS
Manual Compared With Electric Vacuum Aspiration for Treatment of Molar Pregnancy. Obstet Gynecol. 2018 04; 131(4):652-659.
Manual Compared With Electric Vacuum Aspiration for Treatment of Molar Pregnancy.
Duska LR, Garrett L, Henretta M, Ferriss JS, Lee L, Horowitz N
When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. Gynecol Oncol. 2010 Mar; 116(3):374-7.
When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes.
Campos SM, Penson RT, Matulonis U, Horowitz NS, Whalen C, Pereira L, Tyburski K, Roche M, Szymonifka J, Berlin S
A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. 2013 Feb; 128(2):215-20.
A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma.
Vaidya AP, Horowitz NS, Oliva E, Halpern EF, Duska LR
Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma. Gynecol Oncol. 2006 Nov; 103(2):684-7.
Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma.
Ditzel HM, Strickland KC, Meserve EE, Stover E, Konstantinopoulos PA, Matulonis UA, Muto MG, Liu JF, Feltmate C, Horowitz N, Berkowitz RS, Gupta M, Hecht JL, Lin DI, Jochumsen KM, Welch WR, Hirsch MS, Quade BJ, Lee KR, Crum CP, Mutter GL, Nucci MR, Howitt BE
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). Int J Gynecol Pathol. 2019 May; 38(3):230-240.
Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC).
Davis M, Strickland K, Easter SR, Worley M, Feltmate C, Muto M, Horowitz N, Berkowitz R, Feldman S
The impact of health insurance status on the stage of cervical cancer diagnosis at a tertiary care center in Massachusetts. Gynecol Oncol. 2018 07; 150(1):67-72.
The impact of health insurance status on the stage of cervical cancer diagnosis at a tertiary care center in Massachusetts.
Growdon WB, Boisvert SL, Akhavanfard S, Oliva E, Dias-Santagata DC, Kojiro S, Horowitz NS, Iafrate AJ, Borger DR, Rueda BR
Decreased survival in EGFR gene amplified vulvar carcinoma. Gynecol Oncol. 2008 Nov; 111(2):289-97.
Decreased survival in EGFR gene amplified vulvar carcinoma.
Hematology/oncology clinics of North America
New biologic agents for the treatment of gynecologic cancers. Hematol Oncol Clin North Am. 2012 Feb; 26(1):133-56.
New biologic agents for the treatment of gynecologic cancers.
Advances in the surgical management of ovarian cancer. J Reprod Med. 2005 Jun; 50(6):454-66.
Advances in the surgical management of ovarian cancer.
Horowitz NS, Gibb RK, Menegakis NE, Mutch DG, Rader JS, Herzog TJ
Utility and cost-effectiveness of preoperative autologous blood donation in gynecologic and gynecologic oncology patients. Obstet Gynecol. 2002 May; 99(5 Pt 1):771-6.
Utility and cost-effectiveness of preoperative autologous blood donation in gynecologic and gynecologic oncology patients.
Manning-Geist BL, Hicks-Courant K, Gockley AA, Clark RM, Del Carmen MG, Growdon WB, Horowitz NS, Berkowitz RS, Muto MG, Worley MJ
Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery? Gynecol Oncol. 2018 08; 150(2):233-238.
Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?
Siegel CL, Andreotti RF, Cardenes HR, Brown DL, Gaffney DK, Horowitz NS, Javitt MC, Lee SI, Mitchell DG, Moore DH, Rao GG, Royal HD, Small W, Varia MA, Yashar CM
Journal of the American College of Radiology : JACR
ACR Appropriateness Criteria® pretreatment planning of invasive cancer of the cervix. J Am Coll Radiol. 2012 Jun; 9(6):395-402.
ACR Appropriateness Criteria® pretreatment planning of invasive cancer of the cervix.
Horowitz N, Pinto K, Mutch DG, Herzog TJ, Rader JS, Gibb R, Bocker-Edmonston T, and Goodfellow PJ.
Microsatellite instability, hMLH1 methylation, and loss of mismatch repair in endometrial carcinoma and atypical hyperplasia. Gynecologic Oncology. 2002; 86(1):62-68.
Microsatellite instability, hMLH1 methylation, and loss of mismatch repair in endometrial carcinoma and atypical hyperplasia
Padrón L, Rezende-Filho J, Amim-Junior J, Sun SY, Cortés-Charry R, Maestá I, Elias KM, Horowitz NS, Braga A, Berkowitz RS
In Reply. Obstet Gynecol. 2018 07; 132(1):218.
Rauh-Hain JA, Growdon WB, Rodriguez N, Goodman AK, Boruta DM, Schorge JO, Horowitz NS, del Carmen MG
Carcinosarcoma of the ovary: a case-control study. Gynecol Oncol. 2011 Jun 01; 121(3):477-81.
Carcinosarcoma of the ovary: a case-control study.
Rauh-Hain JA, Growdon WB, Schorge JO, Goodman AK, Boruta DM, McCann C, Horowitz NS, del Carmen MG
Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma. Gynecol Oncol. 2010 Nov; 119(2):299-304.
Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma.
Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ
CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol Oncol. 2006 Oct; 103(1):212-8.
CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.
Soong TR, Howitt BE, Miron A, Horowitz NS, Campbell F, Feltmate CM, Muto MG, Berkowitz RS, Nucci MR, Xian W, Crum CP
Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas. J Pathol. 2018 11; 246(3):344-351.
Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas.
Esselen KM, Rodriguez N, Growdon W, Krasner C, Horowitz NS, Campos S
Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy. Gynecol Oncol. 2012 Oct; 127(1):51-4.
Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, Berlin S, Roche MR, Duska LR, Pereira L, Kendall D, Penson RT
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 Dec 10; 26(35):5761-6.
Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ, Feltmate CM, Nucci MR, Swisher EM, Nguyen H, Yang C, Morizane R, Kochupurakkal BS, Do KT, Konstantinopoulos PA, Liu JF, Bonventre JV, Matulonis UA, Shapiro GI, Berkowitz RS, Crum CP, D'Andrea AD
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discov. 2018 11; 8(11):1404-1421.
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.
Rungruang B, Miller A, Richard SD, Hamilton CA, Rodriguez N, Bookman MA, Maxwell GL, Krivak TC, Horowitz NS
Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Jan; 124(1):53-8.
Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study.
Rauh-Hain JA, Winograd D, Growdon WB, Schorge JO, Goodman AK, Boruta DM, Berkowitz RS, Horowitz NS, Del Carmen MG
Prognostic determinants in patients with uterine and ovarian clear carcinoma. Gynecol Oncol. 2012 May; 125(2):376-80.
Prognostic determinants in patients with uterine and ovarian clear carcinoma.
Victoria Diniz M, Sun SY, Barsottini C, Viggiano M, Signorini Filho RC, Sanches Ozane Pimenta B, Elias KM, Horowitz NS, Braga A, Berkowitz RS
Experience With the Use of an Online Community on Facebook for Brazilian Patients With Gestational Trophoblastic Disease: Netnography Study. J Med Internet Res. 2018 09 24; 20(9):e10897.
Experience With the Use of an Online Community on Facebook for Brazilian Patients With Gestational Trophoblastic Disease: Netnography Study.
Horowitz NS, Dehdashti F, Herzog TJ, Rader JS, Powell MA, Gibb RK, Grigsby PW, Siegel BA, Mutch DG
Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol. 2004 Dec; 95(3):546-51.
Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer.
Lee L, Garrett L, Lee H, Oliva E, Horowitz N, Duska LR
Association of clear cell carcinoma of the endometrium with a high rate of venous thromboembolism. J Reprod Med. 2009 Mar; 54(3):133-8.
Association of clear cell carcinoma of the endometrium with a high rate of venous thromboembolism.
Rauh-Hain JA, Nitschmann CC, Worley MJ, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, del Carmen MG, Horowitz NS
Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2013 Apr; 129(1):63-8.
Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.
Obstetrics and gynecology clinics of North America
Role of the ultrasonic surgical aspirator in gynecology. Obstet Gynecol Clin North Am. 2001 Dec; 28(4):775-90.
Role of the ultrasonic surgical aspirator in gynecology.
Cohn DE, Horowitz NS, Mutch DG, Kim SM, Manolitsas T, Fowler JM
Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer? Gynecol Oncol. 2002 Dec; 87(3):243-6.
Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer?
Horowitz NS, Powell MA, Drescher CW, Smith MR, Atwood M, Mate TA, Peters WA
Adequate staging for uterine cancer can be performed through Pfannenstiel incisions. Gynecol Oncol. 2003 Mar; 88(3):404-10.
Adequate staging for uterine cancer can be performed through Pfannenstiel incisions.
Manning-Geist BL, Alimena S, Del Carmen MG, Goodman A, Clark RM, Growdon WB, Horowitz NS, Berkowitz RS, Muto MG, Worley MJ
Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter? Gynecol Oncol. 2019 04; 153(1):63-67.
Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter?
Brown DL, Andreotti RF, Lee SI, Dejesus Allison SO, Bennett GL, Dubinsky T, Glanc P, Horrow MM, Lev-Toaff AS, Horowitz NS, Podrasky AE, Scoutt LM, Zelop CM
ACR appropriateness criteria© ovarian cancer screening. Ultrasound Q. 2010 Dec; 26(4):219-23.
ACR appropriateness criteria© ovarian cancer screening.
Puechl AM, Edwards J, Suri A, Nakayama J, Bean S, Gehrig P, Saks E, Duska L, Broadwater G, Ehrisman J, Horowitz N, Secord AA
The association between progesterone receptor expression and survival in women with adult granulosa cell tumors. Gynecol Oncol. 2019 04; 153(1):74-79.
The association between progesterone receptor expression and survival in women with adult granulosa cell tumors.
Soong TR, Howitt BE, Horowitz N, Nucci MR, Crum CP
The fallopian tube, "precursor escape" and narrowing the knowledge gap to the origins of high-grade serous carcinoma. Gynecol Oncol. 2019 02; 152(2):426-433.
The fallopian tube, "precursor escape" and narrowing the knowledge gap to the origins of high-grade serous carcinoma.
Gockley AA, Fiascone S, Hicks Courant K, Pepin K, Del Carmen M, Clark RM, Goldberg J, Horowitz N, Berkowitz R, Worley M
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma. Int J Gynecol Cancer. 2019 03; 29(3):585-592.
Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
Mora PAR, Sun SY, Velarde GC, Filho JR, Uberti EH, Dos Santos Esteves APV, Elias KM, Horowitz NS, Braga A, Berkowitz RS
Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia? Gynecol Oncol. 2019 05; 153(2):277-285.
Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?
Alimena S, Fiascone S, Krasner C, King M, Horowitz N
A tumor board report of an 83-year-old woman with stage IB grade 3 endometrioid endometrial adenocarcinoma. Curr Probl Cancer. 2019 10; 43(5):443-449.
A tumor board report of an 83-year-old woman with stage IB grade 3 endometrioid endometrial adenocarcinoma.
Veneris JT, Lee EK, Goebel EA, Nucci MR, Lindeman N, Horowitz NS, Lee L, Raut CP, Crotzer D, Matulonis U, Konstantinopoulos PA, Campos S
Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. Gynecol Oncol. 2019 06; 153(3):471-478.
Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer.
American journal of obstetrics and gynecology
A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome. Am J Obstet Gynecol. 2019 10; 221(4):326.e1-326.e7.
A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
Assistant Professor of Obstetrics, Gynecology and Reproductive Biology
Panagiotis Konstantinopoulos, M.D., Ph.D.
Lecturer on Obstetrics, Gynecology and Reproductive Biology, Part-time
Professor of Obstetrics, Gynecology and Reproductive Biology
William H. Baker Professor of Gynecology
Member of the Faculty of Obstetrics, Gynecology and Reproductive Biology
Lee EK, Tan-Wasielewski Z, Matulonis UA, Birrer MJ, Wright AA, Horowitz N, Konstantinopoulos PA, Curtis J, Liu JF
Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol Rep. 2019 Aug; 29:118-122.
Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer.
Continued hCG surveillance following chemotherapy for gestational trophoblastic neoplasia: When is enough enough? Gynecol Oncol. 2019 10; 155(1):1-2.
Continued hCG surveillance following chemotherapy for gestational trophoblastic neoplasia: When is enough enough?
Liu JF, Herold C, Gray KP, Penson RT, Horowitz N, Konstantinopoulos PA, Castro CM, Hill SJ, Curtis J, Luo W, Matulonis UA, Cannistra SA, Dizon DS
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 12 01; 5(12):1731-1738.
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.
Journal of the National Comprehensive Cancer Network : JNCCN
State-of-the-Art Workup and Initial Management of Newly Diagnosed Molar Pregnancy and Postmolar Gestational Trophoblastic Neoplasia. J Natl Compr Canc Netw. 2019 11 01; 17(11):1396-1401.
State-of-the-Art Workup and Initial Management of Newly Diagnosed Molar Pregnancy and Postmolar Gestational Trophoblastic Neoplasia.
Myers AP, Konstantinopoulos PA, Barry WT, Luo W, Broaddus RR, Makker V, Drapkin R, Liu J, Doyle A, Horowitz NS, Meric-Bernstam F, Birrer M, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. Int J Cancer. 2020 07 15; 147(2):413-422.
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.
Considering Changes in the Recommended Human Chorionic Gonadotropin Monitoring After Molar Evacuation. Obstet Gynecol. 2020 01; 135(1):9-11.
Considering Changes in the Recommended Human Chorionic Gonadotropin Monitoring After Molar Evacuation.
Khawajkie Y, Mechtouf N, Nguyen NMP, Rahimi K, Breguet M, Arseneau J, Ronnett BM, Hoffner L, Lazure F, Arnaud M, Peers F, Tan L, Rafea BA, Aguinaga M, Horowitz NS, Ao A, Tan SL, Brown R, Buckett W, Surti U, Hovanes K, Sahoo T, Sauthier P, Slim R
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Comprehensive analysis of 204 sporadic hydatidiform moles: revisiting risk factors and their correlations with the molar genotypes. Mod Pathol. 2020 05; 33(5):880-892.
Comprehensive analysis of 204 sporadic hydatidiform moles: revisiting risk factors and their correlations with the molar genotypes.
Braga A, de Souza Hartung Araújo C, Mora PAR, Paulino E, de Melo AC, Velarde GC, Dos Santos Esteves APV, Junior JA, Filho JR, Elias KM, Horowitz NS, Berkowitz RS
Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend. Gynecol Oncol. 2020 03; 156(3):598-605.
Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend.
Maestá I, Nitecki R, Desmarais CCF, Horowitz NS, Goldstein DP, Elias KM, Berkowitz RS
Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2020 05; 157(2):372-378.
Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia.
Correction: Comprehensive analysis of 204 sporadic hydatidiform moles: revisiting risk factors and their correlations with the molar genotypes. Mod Pathol. 2020 06; 33(6):1237.
Correction: Comprehensive analysis of 204 sporadic hydatidiform moles: revisiting risk factors and their correlations with the molar genotypes.
BJOG : an international journal of obstetrics and gynaecology
Important insights for non-molar choriocarcinoma. BJOG. 2020 08; 127(9):1108.
Important insights for non-molar choriocarcinoma.
Gonzalez R, Gockley AA, Melamed A, Sugrue R, Clark RM, Del Carmen MG, Growdon W, Berkowitz RS, Horowitz NS, Worley MJ
Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer. Gynecol Oncol. 2020 06; 157(3):700-705.
Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer.
Maestá I, de Freitas Segalla Moreira M, Rezende-Filho J, Bianconi MI, Jankilevich G, Otero S, Correa Ramirez LA, Sun SY, Elias K, Horowitz N, Braga A, Berkowitz R
Outcomes in the management of high-risk gestational trophoblastic neoplasia in trophoblastic disease centers in South America. Int J Gynecol Cancer. 2020 09; 30(9):1366-1371.
Outcomes in the management of high-risk gestational trophoblastic neoplasia in trophoblastic disease centers in South America.
Jareemit N, Horowitz NS, Goldstein DP, Berkowitz RS, Elias KM
EMA vs EMACO in the treatment of gestational trophoblastic neoplasia. Gynecol Oncol. 2020 07; 158(1):99-104.
EMA vs EMACO in the treatment of gestational trophoblastic neoplasia.
Freitas F, Braga A, Viggiano M, Velarde LGC, Maesta I, Uberti E, Madi JM, Yela D, Fernandes K, Silveira E, Leal E, Sun SY, Dos Santos Esteves APV, Filho JR, Junior JA, Elias KM, Horowitz NS, Berkowitz RS
Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study. Gynecol Oncol. 2020 08; 158(2):452-459.
Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study.
Schink JC, Filiaci V, Huang HQ, Tidy J, Winter M, Carter J, Anderson N, Moxley K, Yabuno A, Taylor SE, Kushnir C, Horowitz N, Miller DS
An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275. Gynecol Oncol. 2020 08; 158(2):354-360.
An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275.
Li S, Manning-Geist B, Gockley A, Ramos A, Sisodia RC, Del Carmen M, Growdon WB, Horowitz N, Berkowitz R, Worley M
Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer. Int J Gynecol Cancer. 2020 07; 30(7):1052-1057.
Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer.
Braga A, Elias KM, Elias KM, Horowitz NS, Berkowitz RS
How to optimize the management of gestational trophoblastic disease during the coronavirus disease era? Am J Obstet Gynecol. 2020 10; 223(4):604-605.
How to optimize the management of gestational trophoblastic disease during the coronavirus disease era?
Ferraz L, Ramos CAB, Braga A, Velarde LGC, Elias KM, Horowitz NS, Lopes PF, Berkowitz RS
Association between antioxidant vitamins and oxidative stress among patients with a complete hydatidiform mole. Clinics (Sao Paulo). 2020; 75:e1724.
Association between antioxidant vitamins and oxidative stress among patients with a complete hydatidiform mole.
Lee EK, Xiong N, Cheng SC, Barry WT, Penson RT, Konstantinopoulos PA, Hoffman MA, Horowitz N, Dizon DS, Stover EH, Wright AA, Campos SM, Krasner C, Morrissey S, Whalen C, Quinn R, Matulonis UA, Liu JF
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol Oncol. 2020 10; 159(1):72-78.
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Bunnell ME, Donovan BM, Parrack PH, Muto MG, Horowitz NS, Leung SOA
Female adnexal tumor of probable Wolffian Origin - A report of two cases at one institution. Gynecol Oncol Rep. 2020 Aug; 33:100612.
Female adnexal tumor of probable Wolffian Origin - A report of two cases at one institution.
Harvey RA, Elias KM, Lim A, Bercow A, Short D, Horowitz NS, Berkowitz RS, Agarwal R, Seckl MJ
Uterine artery pulsatility index and serum BMP-9 predict resistance to methotrexate therapy in gestational trophoblastic neoplasia: A cohort study. Curr Probl Cancer. 2021 02; 45(1):100622.
Uterine artery pulsatility index and serum BMP-9 predict resistance to methotrexate therapy in gestational trophoblastic neoplasia: A cohort study.
Kanbergs AN, Manning-Geist BL, Pelletier A, Sullivan MW, Del Carmen MG, Horowitz NS, Growdon WB, Clark RM, Muto MG, Worley MJ
Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer. Gynecol Oncol. 2020 12; 159(3):687-691.
Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer.
Lin LH, Maestá I, St Laurent JD, Hasselblatt KT, Horowitz NS, Goldstein DP, Quade BJ, Sun SY, Braga A, Fisher RA, Berkowitz RS, Elias KM
Distinct microRNA profiles for complete hydatidiform moles at risk of malignant progression. Am J Obstet Gynecol. 2021 04; 224(4):372.e1-372.e30.
Distinct microRNA profiles for complete hydatidiform moles at risk of malignant progression.
Outcomes for relapsed versus resistant low risk gestational trophoblastic neoplasia following single-agent chemotherapy. Gynecol Oncol. 2020 12; 159(3):751-757.
Outcomes for relapsed versus resistant low risk gestational trophoblastic neoplasia following single-agent chemotherapy.
Wan C, Keany MP, Dong H, Al-Alem LF, Pandya UM, Lazo S, Boehnke K, Lynch KN, Xu R, Zarrella DT, Gu S, Cejas P, Lim K, Long HW, Elias KM, Horowitz NS, Feltmate CM, Muto MG, Worley MJ, Berkowitz RS, Matulonis UA, Nucci MR, Crum CP, Rueda BR, Brown M, Liu XS, Hill SJ
Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. Cancer Res. 2021 01 01; 81(1):158-173.
Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
Sugrue R, Foley O, Elias KM, Growdon WB, Sisodia RMC, Berkowitz RS, Horowitz NS
Outcomes of minimally invasive versus open abdominal hysterectomy in patients with gestational trophoblastic disease. Gynecol Oncol. 2021 02; 160(2):445-449.
Outcomes of minimally invasive versus open abdominal hysterectomy in patients with gestational trophoblastic disease.
Braga A, Elias KM, Horowitz NS, Berkowitz RS
When less is more: regarding the use of chest X-ray instead of computed tomography in screening for pulmonary metastasis in postmolar gestational trophoblastic neoplasia. Br J Cancer. 2021 03; 124(6):1033-1034.
When less is more: regarding the use of chest X-ray instead of computed tomography in screening for pulmonary metastasis in postmolar gestational trophoblastic neoplasia.
Leung SOA, Feldman S, Kalyanaraman R, Shanmugam V, Worley MJ, Berkowitz RS, Horowitz NS, Feltmate CM, Muto MG, Lee LJ, King MT, Einarsson JI, Ajao MO, Elias KM
American journal of reproductive immunology (New York, N.Y. : 1989)
Triaging abnormal cervical cancer screening tests using p16INK4a detection by ELISA on fresh cervical samples. Am J Reprod Immunol. 2021 07; 86(1):e13394.
Triaging abnormal cervical cancer screening tests using p16INK4a detection by ELISA on fresh cervical samples.
Braga A, Padrón L, Balen JL, Elias KM, Horowitz NS, Berkowitz RS
Journal of minimally invasive gynecology
Video Hysteroscopy in the Diagnosis of Molar Pregnancy in two Challenging Situations: Complete Mole with Normal hCG and Partial Mole with Early Gestational Age. J Minim Invasive Gynecol. 2021 08; 28(8):1448-1449.
Video Hysteroscopy in the Diagnosis of Molar Pregnancy in two Challenging Situations: Complete Mole with Normal hCG and Partial Mole with Early Gestational Age.
Best practice & research. Clinical obstetrics & gynaecology
Treatment of high-risk gestational trophoblastic neoplasia and chemoresistance/relapsed disease. Best Pract Res Clin Obstet Gynaecol. 2021 Jul; 74:81-96.
Treatment of high-risk gestational trophoblastic neoplasia and chemoresistance/relapsed disease.
Schrier E, Xiong N, Thompson E, Poort H, Schumer S, Liu JF, Krasner C, Campos SM, Horowitz NS, Feltmate C, Konstantinopoulos PA, Dinardo MM, Tayob N, Matulonis UA, Patel M, Wright AA
Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. Gynecol Oncol. 2021 05; 161(2):581-586.
Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors.
Manning-Geist BL, Sullivan MW, Sarda V, Gockley AA, Del Carmen MG, Matulonis U, Growdon WB, Horowitz NS, Berkowitz RS, Clark RM, Worley MJ
Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer. Ann Surg Oncol. 2021 Oct; 28(11):6705-6713.
Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer.
Liu JF, Xiong N, Campos SM, Wright AA, Krasner C, Schumer S, Horowitz N, Veneris J, Tayob N, Morrissey S, West G, Quinn R, Matulonis UA, Konstantinopoulos PA
Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol. 2021 05 10; 39(14):1531-1539.
Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma.
Lynch KN, Liu JF, Kesten N, Chow KH, Shetty A, He R, Afreen MF, Yuan L, Matulonis UA, Growdon WB, Muto MG, Horowitz NS, Feltmate CM, Worley MJ, Berkowitz RS, Crum CP, Rueda BR, Hill SJ
Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 Interactions. Cancers (Basel). 2021 May 03; 13(9).
Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 Interactions.
Braga A, Padrón L, Rezende-Filho J, Elias K, Horowitz N, Berkowitz R
Treatment of hydatidiform mole using manual vacuum aspiration: technical and tactical aspects. Int J Gynecol Cancer. 2021 09; 31(9):1299-1300.
Treatment of hydatidiform mole using manual vacuum aspiration: technical and tactical aspects.
St Laurent JD, Lin LH, Owen DM, Maestá I, Castaneda A, Hasselblatt KT, Goldstein DP, Horowitz NS, Berkowitz RS, Elias KM
Reproductive sciences (Thousand Oaks, Calif.)
Loss of Selenoprotein Iodothyronine Deiodinase 3 Expression Correlates with Progression of Complete Hydatidiform Mole to Gestational Trophoblastic Neoplasia. Reprod Sci. 2021 11; 28(11):3200-3211.
Loss of Selenoprotein Iodothyronine Deiodinase 3 Expression Correlates with Progression of Complete Hydatidiform Mole to Gestational Trophoblastic Neoplasia.
Chung TKH, Doran G, Cheung TH, Yim SF, Yu MY, Worley MJ, Elias KM, Thorner AR, Pedamallu CS, Ojesina AI, Lau KM, Ducar MD, Wong RRY, Wang VW, Nag A, Wollison BM, Dalgarno A, Lee JHS, Yeung SY, Wong L, Horowitz NS, Davis MR, Leung SA, Mu Y, Mok SC, Chan PKS, Lawrence MS, Crum CP, Chiu RWK, Berkowitz RS, Wong YF
Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes. Cancers (Basel). 2021 Jun 28; 13(13).
Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes.
Braga A, Paiva G, Ghorani E, Freitas F, Velarde LGC, Kaur B, Unsworth N, Lozano-Kuehne J, Dos Santos Esteves APV, Rezende Filho J, Amim J, Aguiar X, Sarwar N, Elias KM, Horowitz NS, Berkowitz RS, Seckl MJ
Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study. Lancet Oncol. 2021 08; 22(8):1188-1198.
Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study.
Krasner CN, Campos SM, Young CL, Chadda KR, Lee H, Birrer MJ, Horowitz NS, Konstantinopoulos PA, D'Ascanio AM, Matulonis UA, Penson RT
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer. Gynecol Oncol. 2021 09; 162(3):661-666.
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
Poli JG, Paiva G, Freitas F, Mora P, Velarde LGC, Junior JA, Filho JR, Elias KM, Horowitz NS, Braga A, Berkowitz RS
Folinic acid rescue during methotrexate treatment for low-risk gestational trophoblastic neoplasia - How much is just right? Gynecol Oncol. 2021 09; 162(3):638-644.
Folinic acid rescue during methotrexate treatment for low-risk gestational trophoblastic neoplasia - How much is just right?
Greer A, Gockley A, Manning-Geist B, Melamed A, Sisodia RC, Berkowitz R, Horowitz N, Del Carmen M, Growdon WB, Worley M
Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer. Int J Gynecol Cancer. 2021 10; 31(10):1341-1347.
Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer.
Gockley AA, Lin LH, Davis M, Melamed A, Rizzo A, Sun SY, Elias K, Goldstein DP, Berkowitz RS, Horowitz NS
Impact of clinical characteristics on human chorionic gonadotropin regression after molar pregnancy. Clinics (Sao Paulo). 2021; 76:e2830.
Impact of clinical characteristics on human chorionic gonadotropin regression after molar pregnancy.
Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia
Challenges in the Treatment of Low-risk Gestational Trophoblastic Neoplasia. Rev Bras Ginecol Obstet. 2021 Jul; 43(7):503-506.
Challenges in the Treatment of Low-risk Gestational Trophoblastic Neoplasia.
Elias KM, Braga A, Horowitz NS, Berkowitz RS
A novel alternative to cytotoxic chemotherapy for gestational trophoblastic disease. Lancet Oncol. 2021 11; 22(11):1490-1491.
A novel alternative to cytotoxic chemotherapy for gestational trophoblastic disease.
Madi JM, Paganella MP, Litvin IE, Viggiano M, Wendland EM, Elias KM, Horowitz NS, Braga A, Berkowitz RS
Perinatal outcomes of first pregnancy after chemotherapy for gestational trophoblastic neoplasia: a systematic review of observational studies and meta-analysis. Am J Obstet Gynecol. 2022 05; 226(5):633-645.e8.
Perinatal outcomes of first pregnancy after chemotherapy for gestational trophoblastic neoplasia: a systematic review of observational studies and meta-analysis.
Horowitz NS, Eskander RN, Adelman MR, Burke W
Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation. Gynecol Oncol. 2021 12; 163(3):605-613.
Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation.
Shinagare AB, Sadowski EA, Park H, Brook OR, Forstner R, Wallace SK, Horowitz JM, Horowitz N, Javitt M, Jha P, Kido A, Lakhman Y, Lee SI, Manganaro L, Maturen KE, Nougaret S, Poder L, Rauch GM, Reinhold C, Sala E, Thomassin-Naggara I, Vargas HA, Venkatesan A, Nikolic O, Rockall AG
Ovarian cancer reporting lexicon for computed tomography (CT) and magnetic resonance (MR) imaging developed by the SAR Uterine and Ovarian Cancer Disease-Focused Panel and the ESUR Female Pelvic Imaging Working Group. Eur Radiol. 2022 May; 32(5):3220-3235.
Ovarian cancer reporting lexicon for computed tomography (CT) and magnetic resonance (MR) imaging developed by the SAR Uterine and Ovarian Cancer Disease-Focused Panel and the ESUR Female Pelvic Imaging Working Group.
Konstantinopoulos PA, Cheng SC, Supko JG, Polak M, Wahner-Hendrickson AE, Ivy SP, Bowes B, Sawyer H, Basada P, Hayes M, Curtis J, Horowitz N, Wright AA, Campos SM, Ivanova EV, Paweletz CP, Palakurthi S, Liu JF, D'Andrea AD, Gokhale PC, Chowdhury D, Matulonis UA, Shapiro GI
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours. Br J Cancer. 2022 04; 126(7):1027-1036.
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.
Campos SM, Berlin S, Krasner CN, Whalen C, Atkinson T, Meegan K, Pereira L, Tyburski K, Lou W, Lee H, Horowitz N, Penson RT
A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies. Cancer Chemother Pharmacol. 2022 03; 89(3):423-430.
A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies.
Yoon JY, Chapel DB, Goebel E, Qian X, Mito JK, Horowitz NS, Miron A, Soong TR, Xian W, Crum CP
Genomic catastrophe, the peritoneal cavity and ovarian cancer prevention. J Pathol. 2022 07; 257(3):255-261.
Genomic catastrophe, the peritoneal cavity and ovarian cancer prevention.
Georgiou M, Ntavelou P, Stokes W, Roy R, Maher GJ, Stoilova T, Choo JAMY, Rakhit CP, Martins M, Ajuh P, Horowitz N, Berkowitz RS, Elias K, Seckl MJ, Pardo OE
ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma. Oncogene. 2022 04; 41(18):2540-2554.
ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma.
Branco-Silva M, Maesta I, Elias K, Berkowitz RS, Abbade JF, Horowitz NS
Consolidation chemotherapy in postmolar low-risk gestational trophoblastic neoplasia: a systematic review protocol. BMJ Open. 2022 Feb 24; 12(2):e059484.
Consolidation chemotherapy in postmolar low-risk gestational trophoblastic neoplasia: a systematic review protocol.
Ramos MM, Maesta I, de Araújo Costa RA, Mazeto GMFS, Horowitz NS, Elias KM, Braga A, Berkowitz RS
Clinical characteristics and thyroid function in complete hydatidiform mole complicated by hyperthyroidism. Gynecol Oncol. 2022 04; 165(1):137-142.
Clinical characteristics and thyroid function in complete hydatidiform mole complicated by hyperthyroidism.
Stover EH, Xiong N, Myers AP, Tayob N, Engvold V, Polak M, Broaddus RR, Makker V, Drapkin R, Liu JF, Horowitz NS, Meric-Bernstam F, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN, Konstantinopoulos PA
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. Gynecol Oncol Rep. 2022 Apr; 40:100974.
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma.
Ramírez LAC, Maestá I, Bianconi MI, Jankilevich G, Otero S, Mejía CRV, Cortés-Charry R, Elias KM, Horowitz NS, Seckl M, Berkowitz RS
Clinical Presentation, Treatment Outcomes, and Resistance-related Factors in South American Women with Low-risk Postmolar Gestational Trophoblastic Neoplasia. Rev Bras Ginecol Obstet. 2022 Aug; 44(8):746-754.
Clinical Presentation, Treatment Outcomes, and Resistance-related Factors in South American Women with Low-risk Postmolar Gestational Trophoblastic Neoplasia.
Correction: ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma. Oncogene. 2022 Jun; 41(26):3510.
Correction: ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma.
Konstantinopoulos PA, Gockley AA, Xiong N, Krasner C, Horowitz N, Campos S, Wright AA, Liu JF, Shea M, Yeku O, Castro C, Polak M, Lee EK, Sawyer H, Bowes B, Moroney J, Cheng SC, Tayob N, Bouberhan S, Spriggs D, Penson RT, Fleming GF, Nucci MR, Matulonis UA
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncol. 2022 09 01; 8(9):1317-1322.
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.
Campos V, Paiva G, Padron L, Freitas F, Pedrotti LG, Sun SY, Viggiano M, Oliveira L, Rohr L, Madi JM, Arrym TP, Oliveira P, Dos Santos Esteves APV, Junior JA, Filho JR, Elias KM, Horowitz NS, Braga A, Berkowitz RS
Influence of COVID-19 pandemic on molar pregnancy and postmolar gestational trophoblastic neoplasia: An observational study. BJOG. 2023 02; 130(3):292-302.
Influence of COVID-19 pandemic on molar pregnancy and postmolar gestational trophoblastic neoplasia: An observational study.
Campos S, Matulonis U, Berlin S, Horowitz N, Liu J, Krasner C, Hang L, Zarwan C, Barry W, Colella T, Whalen C, Shoni M, Lundquist C, Birrer MJ, Penson R
International journal of clinical oncology
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors. Int J Clin Oncol. 2022 Dec; 27(12):1881-1890.
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors.
Konstantinopoulos PA, Lee EK, Xiong N, Krasner C, Campos S, Kolin DL, Liu JF, Horowitz N, Wright AA, Bouberhan S, Penson RT, Yeku O, Bowes B, Needham H, Hayes M, Sawyer H, Polak M, Shea M, Cheng SC, Castro C, Matulonis UA
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer. J Clin Oncol. 2023 01 20; 41(3):599-608.
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.
Trivedi MS, Arber N, Friedman E, Garber JE, Holcomb K, Horowitz NS, Wright JD, Lee JJ, Vornik LA, Abutaseh S, Castile T, Sauter ER, Dimond E, Heckman-Stoddard BM, House M, Samimi G, Brown PH, Crew KD
Cancer prevention research (Philadelphia, Pa.)
Lessons from the Failure to Complete a Trial of Denosumab in Women With a Pathogenic BRCA1/2 Variant Scheduling Risk-Reducing Salpingo-Oophorectomy. Cancer Prev Res (Phila). 2022 11 01; 15(11):721-726.
Lessons from the Failure to Complete a Trial of Denosumab in Women With a Pathogenic BRCA1/2 Variant Scheduling Risk-Reducing Salpingo-Oophorectomy.
Braga A, Paiva G, Cattai CJ, Elias KM, Horowitz NS, Berkowitz RS
Current chemotherapeutic options for the treatment of gestational trophoblastic disease. Expert Opin Pharmacother. 2023 Feb; 24(2):245-258.
Current chemotherapeutic options for the treatment of gestational trophoblastic disease.
Braga A, Canelas AC, Torres B, Maesta I, Giongo Pedrotti L, Bessel M, Vieira Dos Santos Esteves AP, Amim Junior J, Rezende Filho J, Elias KM, Horowitz NS, Berkowitz RS
Neutrophil/lymphocyte ratio and other blood cell component counts are not associated with the development of postmolar gestational trophoblastic neoplasia. PLoS One. 2022; 17(12):e0277892.
Neutrophil/lymphocyte ratio and other blood cell component counts are not associated with the development of postmolar gestational trophoblastic neoplasia.
Braga A, Andrade T, do Carmo Borges de Souza M, Campos V, Freitas F, Maestá I, Sun SY, Pedrotti LG, Bessel M, Junior JA, Filho JR, Elias KM, Horowitz NS, Berkowitz RS
Presentation, medical complications and development of gestational trophoblastic neoplasia of hydatidiform mole after intracytoplasmic sperm injection as compared to hydatidiform mole after spontaneous conception - a retrospective cohort study and literature review. Gynecol Oncol. 2023 03; 170:179-185.
Presentation, medical complications and development of gestational trophoblastic neoplasia of hydatidiform mole after intracytoplasmic sperm injection as compared to hydatidiform mole after spontaneous conception - a retrospective cohort study and literature review.
Jareemit N, Therasakvichya S, Freitas F, Paiva G, Ramírez LAC, Berkowitz RS, Horowitz NS, Maestá I, Fülöp V, Braga A, Elias KM
EMACO for treatment of gestational trophoblastic neoplasia: A multinational multicenter study. Gynecol Oncol. 2023 03; 170:114-122.
EMACO for treatment of gestational trophoblastic neoplasia: A multinational multicenter study.
Braga A, Balthar E, Souza LCS, Samora M, Rech M, Madi JM, Junior JA, Filho JR, Elias KM, Horowitz NS, Sun SY, Berkowitz RS
Immunotherapy in the treatment of chemoresistant gestational trophoblastic neoplasia - systematic review with a presentation of the first 4 Brazilian cases. Clinics (Sao Paulo). 2023; 78:100260.
Immunotherapy in the treatment of chemoresistant gestational trophoblastic neoplasia - systematic review with a presentation of the first 4 Brazilian cases.
Silva VARD, Maestá I, Costa RAA, Campos AÁ, Braga A, Horowitz N, Elias KM, Berkowitz R
Geographical Health District and Distance Traveled Influence on Clinical Status at Admission of Patients with Gestational Trophoblastic Disease. Rev Bras Ginecol Obstet. 2023 Jul; 45(7):e384-e392.
Geographical Health District and Distance Traveled Influence on Clinical Status at Admission of Patients with Gestational Trophoblastic Disease.
Braga A, Lopes R, Campos V, Freitas F, Maestá I, Sun SY, Pedrotti LG, Bessel M, de Sousa CB, Leal E, Yela D, Uberti E, Madi JM, Viggiano M, Junior JA, Filho JR, Elias KM, Horowitz NS, Berkowitz RS
The impact of the distance traveled between residence and gestational trophoblastic neoplasia reference center and clinical outcomes in Brazilian women. Gynecol Oncol. 2023 09; 176:130-138.
The impact of the distance traveled between residence and gestational trophoblastic neoplasia reference center and clinical outcomes in Brazilian women.
Horowitz NS, Deng W, Peterson I, Mannel RS, Thompson S, Lokich E, Myers T, Hanjani P, O'Malley DM, Chung KY, Miller DS, Ueland FR, Dizon DS, Miller A, Mayadev JS, Leath CA, Monk BJ
Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279. J Clin Oncol. 2024 Jun 01; 42(16):1914-1921.
Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279.
Pozzar RA, Enzinger AC, Howard C, Tavormina A, Matulonis UA, Campos S, Liu JF, Horowitz N, Konstantinopoulos PA, Krasner C, Wall JA, Sciacca K, Meyer LA, Lindvall C, Wright AA
Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial. Gynecol Oncol. 2024 Sep; 188:1-7.
Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial.
Wall JA, Pozzar RA, Enzinger AC, Tavormina A, Howard C, Matulonis UA, Liu JF, Horowitz N, Meyer LA, Wright AA
Improving the palliative-procedure decision-making process for patients with peritoneal carcinomatosis: A secondary analysis. Gynecol Oncol. 2024 Sep; 188:125-130.
Improving the palliative-procedure decision-making process for patients with peritoneal carcinomatosis: A secondary analysis.
Young AN, Lin LH, Abel MK, Badhey MO, Lechner A, Horowitz NS, Berkowitz RS, Parra-Herran C, Elias KM
Atypical placental site nodules: Clinicopathologic features, management and patient outcomes in an institutional series. Gynecol Oncol. 2024 Nov; 190:215-221.
Atypical placental site nodules: Clinicopathologic features, management and patient outcomes in an institutional series.
Maestá I, Growdon WB, Goldstein DP, Bernstein MR, Horowitz NS, Rudge MV, Berkowitz RS
Prognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasia. Gynecol Oncol. 2013 Aug; 130(2):312-6.
Prognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasia.
Rauh-Hain JA, Shoni M, Schorge JO, Goodman A, Horowitz NS, del Carmen MG
Prognostic determinants in patients with uterine and ovarian carcinosarcoma. J Reprod Med. 2013 Jul-Aug; 58(7-8):297-304.
Prognostic determinants in patients with uterine and ovarian carcinosarcoma.
Alimena S, Elias KM, Horowitz NS, Berkowitz RS
Initial Diagnosis and Treatment of Low-Risk Gestational Trophoblastic Neoplasia. Hematol Oncol Clin North Am. 2024 Dec; 38(6):1233-1244.
Initial Diagnosis and Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
75 Years of Advancement in Gestational Trophoblastic Disease. Hematol Oncol Clin North Am. 2024 Dec; 38(6):xiii-xv.
75 Years of Advancement in Gestational Trophoblastic Disease.
Surgical Management of Gestational Trophoblastic Neoplasia. Hematol Oncol Clin North Am. 2024 Dec; 38(6):1287-1295.
Surgical Management of Gestational Trophoblastic Neoplasia.
Braga A, Paiva G, Alevato R, Saldanha P, Elias KM, Horowitz NS, Berkowitz RS
Treatment of High-Risk Gestational Trophoblastic Neoplasia. Hematol Oncol Clin North Am. 2024 Dec; 38(6):1245-1258.
Treatment of High-Risk Gestational Trophoblastic Neoplasia.
Ultra High-risk Gestational Trophoblastic Neoplasia. Hematol Oncol Clin North Am. 2024 Dec; 38(6):1259-1264.
Ultra High-risk Gestational Trophoblastic Neoplasia.
Braga A, Paiva G, Barcellos M, Elias KM, Horowitz NS, Berkowitz RS
Diagnosis and Management of Molar Pregnancies. Hematol Oncol Clin North Am. 2024 Dec; 38(6):1149-1159.
Diagnosis and Management of Molar Pregnancies.
Branco-Silva M, Maestá I, Horowitz N, Elias K, Seckl M, Berkowitz R
Recurrence and resistance risk factors in low- risk gestational trophoblastic neoplasia. Int J Gynecol Cancer. 2025 Nov; 35(11):101876.
Recurrence and resistance risk factors in low- risk gestational trophoblastic neoplasia.
Wang V, Elias KM, Berkowitz RS, Horowitz NS
Placental Site Trophoblastic Tumors and Epithelioid Trophoblastic Tumors. Hematol Oncol Clin North Am. 2024 Dec; 38(6):1277-1286.
Placental Site Trophoblastic Tumors and Epithelioid Trophoblastic Tumors.
Rauh-Hain JA, Melamed A, Pareja R, May T, Sinno A, McNally L, Horowitz NS, De Iaco P, Michener CM, Van Lonkhuijzen L, Iniesta MD, Yuan Y, Ramirez PT, Fagotti A
Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy in High-Grade Epithelial Ovarian Cancer: A LANCE Randomized Clinical Trial. JAMA Netw Open. 2024 11 04; 7(11):e2446325.
Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy in High-Grade Epithelial Ovarian Cancer: A LANCE Randomized Clinical Trial.
Rodriguez N, Miller A, Richard SD, Rungruang B, Hamilton CA, Bookman MA, Maxwell GL, Horowitz NS, Krivak TC
Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182. Gynecol Oncol. 2013 Sep; 130(3):487-92.
Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182.
Cham S, Pozzar RA, Horowitz N, Feltmate C, Matulonis UA, Lai JC, Wright AA
The pervasive impact of frailty on ovarian cancer care and the role of prehabilitation: Qualitative perspectives of key stakeholders. J Geriatr Oncol. 2025 03; 16(2):102173.
The pervasive impact of frailty on ovarian cancer care and the role of prehabilitation: Qualitative perspectives of key stakeholders.
Rauh-Hain JA, Guseh SH, Esselen KM, Growdon WB, Schorge JO, Horowitz NS, Krasner CN, del Carmen MG, Birrer MJ, Dizon DS
Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2013 Sep; 23(7):1219-25.
Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer.
Suri A, Carter EB, Horowitz N, Denslow S, Gehrig PA
Factors associated with an increased risk of recurrence in women with ovarian granulosa cell tumors. Gynecol Oncol. 2013 Nov; 131(2):321-4.
Factors associated with an increased risk of recurrence in women with ovarian granulosa cell tumors.
Tyan K, Liu KX, Smart AC, Feltmate CM, Horowitz NS, Muto MG, Worley MJ, Elias KM, Liu JF, Wright AA, Konstantinopoulos PA, Campos SM, Matulonis UA, Franco I, Lee LJ, King MT, Dyer MA
Role of adjuvant radiotherapy modality on clinical outcomes for early-stage uterine carcinosarcoma. Gynecol Oncol. 2025 Apr; 195:75-81.
Role of adjuvant radiotherapy modality on clinical outcomes for early-stage uterine carcinosarcoma.
Horowitz NS, St Laurent JD, Berkowitz RS
Prevention of gestational trophoblastic neoplasia with actinomycin -D at the time of evacuation: A matter of routine practice or reserve for special circumstances? Gynecol Oncol. 2025 Feb; 193:A1-A2.
Prevention of gestational trophoblastic neoplasia with actinomycin -D at the time of evacuation: A matter of routine practice or reserve for special circumstances?
Straczkiewicz M, Keating NL, Schonholz SM, Matulonis UA, Horowitz N, Campos S, Onnela JP, Wright AA
medRxiv : the preprint server for health sciences
Smartphone-based measures as real-world indicators of functional status in advanced cancer patients. medRxiv. 2025 Feb 07.
Smartphone-based measures as real-world indicators of functional status in advanced cancer patients.
Mitchell DG, Javitt MC, Glanc P, Bennett GL, Brown DL, Dubinsky T, Harisinghani MG, Harris RD, Horowitz NS, Pandharipande PV, Pannu HK, Podrasky AE, Royal HD, Shipp TD, Siegel CL, Simpson L, Wong-You-Cheong JJ, Zelop CM
ACR appropriateness criteria staging and follow-up of ovarian cancer. J Am Coll Radiol. 2013 Nov; 10(11):822-7.
ACR appropriateness criteria staging and follow-up of ovarian cancer.
Fitzgerald KJ, Konstantinopoulos P, Matulonis U, Liu J, Horowitz N, Lee E, Kolin DL, Lee L, King M
A phase I clinical trial of radiation therapy, durvalumab and tremelimumab in recurrent gynecologic cancer. Gynecol Oncol. 2025 Jun; 197:51-56.
A phase I clinical trial of radiation therapy, durvalumab and tremelimumab in recurrent gynecologic cancer.
Barcellos M, Braga A, Rech MM, de Oliveira SA, Madi JM, Sun SY, de Rezende-Filho J, Elias KM, Horowitz NS, Berkowitz RS
Pembrolizumab in gestational trophoblastic neoplasia: Systematic review and meta-analysis with sub-group analysis of potential prognostic factors. Clinics (Sao Paulo). 2025; 80:100583.
Pembrolizumab in gestational trophoblastic neoplasia: Systematic review and meta-analysis with sub-group analysis of potential prognostic factors.
Konstantinopoulos PA, Cai M, Lee EK, Krasner C, Campos SM, Liu JF, Horowitz NS, Shea M, Parsons HA, Wright AA, Bouberhan S, Penson RT, Yeku O, Hayes M, Sawyer H, Polak M, Castro CM, Cheng SC, Weipert CM, Matulonis UA
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer. JCO Precis Oncol. 2025 Apr; 9:e2400882.
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer.
Alimena S, Reid H, Bercow A, Feltmate C, St Laurent J, May T, Berkowitz R, Horowitz N, Davis M
Trends in sentinel lymph node evaluation for vulvar melanoma in the United States from 2012 to 2018. Gynecol Oncol. 2025 May; 196:175-181.
Trends in sentinel lymph node evaluation for vulvar melanoma in the United States from 2012 to 2018.
Viswanathan AN, Lee H, Berkowitz R, Berlin S, Campos S, Feltmate C, Horowitz N, Muto M, Sadow CA, Matulonis U
A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer. Gynecol Oncol. 2014 Jan; 132(1):55-60.
A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer.
Smartphone-Based Measures as Indicators of Functional Status in Patients With Advanced Cancer. JAMA Netw Open. 2025 Sep 02; 8(9):e2532488.
Smartphone-Based Measures as Indicators of Functional Status in Patients With Advanced Cancer.
Conner JR, Meserve E, Pizer E, Garber J, Roh M, Urban N, Drescher C, Quade BJ, Muto M, Howitt BE, Pearlman MD, Berkowitz RS, Horowitz N, Crum CP, Feltmate C
Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol Oncol. 2014 Feb; 132(2):280-6.
Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations.
Lin LH, Hasselblatt KT, Parra-Herran C, Horowitz NS, Berkowitz RS, Quade BJ, Elias KM
Antibody-drug Conjugate Biomarker Expression in Gestational Trophoblastic Disease: Folate Receptor Alpha, Nectin-4, Trop-2, and Tissue Factor. Int J Gynecol Pathol. 2026 Jan 01; 45(1):28-38.
Antibody-drug Conjugate Biomarker Expression in Gestational Trophoblastic Disease: Folate Receptor Alpha, Nectin-4, Trop-2, and Tissue Factor.
Desmarais CCF, Maestá I, Sun SY, de Rezende-Filho J, de Araújo Costa RA, Lin LH, Branco-Silva M, Horowitz NS, Elias KM, Braga A, Berkowitz RS
Initial Treatment and Outcomes of Complete Hydatidiform Mole in Women 40 Years or Older: A Multicenter Cohort Study. Cancers (Basel). 2025 Sep 26; 17(19).
Initial Treatment and Outcomes of Complete Hydatidiform Mole in Women 40 Years or Older: A Multicenter Cohort Study.
Davis M, Rauh-Hain JA, Andrade C, Boruta DM, Schorge JO, Horowitz NS, May T, del Carmen MG
Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary. Gynecol Oncol. 2014 Mar; 132(3):760-6.
Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary.
Vargas R, Rauh-Hain JA, Clemmer J, Clark RM, Goodman A, Growdon WB, Schorge JO, Del Carmen MG, Horowitz NS, Boruta DM
Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol. 2014 May; 133(2):216-20.
Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis.
Gestational trophoblastic disease: presentations from the XVIIth World Congress on Gestational Trophoblastic Diseases. J Reprod Med. 2014 May-Jun; 59(5-6):187.
Gestational trophoblastic disease: presentations from the XVIIth World Congress on Gestational Trophoblastic Diseases.
Stauss HJ, Davies H, Sadovnikova E, Chain B, Horowitz N, Sinclair C
Proceedings of the National Academy of Sciences of the United States of America
Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus. Proc Natl Acad Sci U S A. 1992 Sep 01; 89(17):7871-5.
Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus.
Moshkowitz M, Horowitz N, Leshno M, Halpern Z
Halitosis and gastroesophageal reflux disease: a possible association. Oral Dis. 2007 Nov; 13(6):581-5.
Halitosis and gastroesophageal reflux disease: a possible association.
Horowitz N, Moshkowitz M, Leshno M, Ribak J, Birkenfeld S, Kenet G, Halpern Z
Clinical trial: evaluation of a clinical decision-support model for upper abdominal complaints in primary-care practice. Aliment Pharmacol Ther. 2007 Nov 01; 26(9):1277-83.
Clinical trial: evaluation of a clinical decision-support model for upper abdominal complaints in primary-care practice.
Braga A, Chagas M, Asrani M, Soares JP, Sun SY, Araujo Júnior E, Mattar R, Amim Junior J, Rezende-Filho J, Horowitz NS, Berkowitz RS
Diagnosis and Surgical Treatment of Hydatidiform Mole. Diagnostics (Basel). 2025 Aug 18; 15(16).
Diagnosis and Surgical Treatment of Hydatidiform Mole.
Tulchinsky H, Averboukh F, Horowitz N, Rabau M, Klausner JM, Halpern Z, Dotan I
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
Restorative proctocolectomy impairs fertility and pregnancy outcomes in women with ulcerative colitis. Colorectal Dis. 2013 Jul; 15(7):842-7.
Restorative proctocolectomy impairs fertility and pregnancy outcomes in women with ulcerative colitis.
Etiology, Natural History, and Management of Recent Advances in Molar Pregnancy. Obstet Gynecol. 2025 Oct 01; 146(4):451-465.
Etiology, Natural History, and Management of Recent Advances in Molar Pregnancy.
Maesta I, Silva VAR, Costa RAA, Carvalho TH, Branco-Silva M, Braga A, Elias KM, Berkowitz RS, Horowitz NS
Home-based treatment of low-risk gestational trophoblastic neoplasia with 8-day methotrexate/folinic acid. Gynecol Oncol. 2026 Jan; 204:235-241.
Home-based treatment of low-risk gestational trophoblastic neoplasia with 8-day methotrexate/folinic acid.
Wittmann T, Horowitz N, Benyamini N, Henig I, Zuckerman T, Rowe JM, Kra-Oz Z, Szwarcwort Cohen M, Oren I, Avivi I
JC polyomavirus reactivation is common following allogeneic stem cell transplantation and its preemptive detection may prevent lethal complications. Bone Marrow Transplant. 2015 Jul; 50(7):984-91.
JC polyomavirus reactivation is common following allogeneic stem cell transplantation and its preemptive detection may prevent lethal complications.
Response to commentary on "pembrolizumab in gestational trophoblastic neoplasia: systematic review and meta-analysis with sub-group analysis of potential prognostic factors". Clinics (Sao Paulo). 2025 Jan-Dec; 80:100713.
Response to commentary on "pembrolizumab in gestational trophoblastic neoplasia: systematic review and meta-analysis with sub-group analysis of potential prognostic factors".
Yoo SS, Banish K, Fahmi A, Glasener C, Yoon K, Betharia S, Zhang Y, Elias K, Horowitz N
Focused Ultrasound-mediated Disruption of Plasma Protein Binding Enhances Chemotherapeutic Effects of Paclitaxel on Xenografted Ovarian Cancer in Mice. Anticancer Res. 2025 11; 45(11):4697-4715.
Focused Ultrasound-mediated Disruption of Plasma Protein Binding Enhances Chemotherapeutic Effects of Paclitaxel on Xenografted Ovarian Cancer in Mice.
Konstantinopoulos PA, Zhou N, Penson RT, Le TV, Campos S, Krasner C, Wright AA, Porter R, Horowitz N, Bouberhan S, Liu JF, Hindenach S, Sawyer H, Koppermann L, Hayes M, Polak M, Shea M, Widick P, Cheng SC, Castro C, Beumer JH, Matulonis UA, Lee EK
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial. Nat Commun. 2025 Dec 03; 17(1):395.
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial.
Tewari S, Koelker-Wolfe E, Pelletier A, St Laurent J, Campos S, Liu J, Matulonis U, Horowitz N, Wang V
The impact of romiplostim use for chemotherapy induced thrombocytopenia on immediate and long-term outcomes in gynecologic malignancies. Gynecol Oncol. 2025 Dec; 203:53-58.
The impact of romiplostim use for chemotherapy induced thrombocytopenia on immediate and long-term outcomes in gynecologic malignancies.
Paiva G, Braga A, Artimos de Oliveira S, Sun SY, Maestá I, Pedrotti LG, Bessel M, Amim-Junior J, Rezende-Filho J, Elias K, Berkowitz R, Horowitz N
Tracking the Cesarean Delivery-Postmolar Gestational Trophoblastic Neoplasia Link. Obstet Gynecol. 2026 Apr 01; 147(4):575-584.
Tracking the Cesarean Delivery-Postmolar Gestational Trophoblastic Neoplasia Link.
Barcellos MB, Braga A, Alevato R, Turon S, Callado GY, Artimos S, Sun SY, Rezende-Filho J, Araujo Júnior E, de Melo AC, Berkowitz RS, Horowitz NS, Granese R
Checkpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity. Adv Ther. 2026 Mar; 43(3):1060-1081.
Checkpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity.
Worley MJ, Guseh SH, Rauh-Hain JA, Esselen KM, Muto MG, Feltmate CM, Berkowitz RS, Del Carmen MG, Schorge JO, Horowitz NS
What is the optimal treatment for obese patients with advanced ovarian carcinoma? Am J Obstet Gynecol. 2014 Sep; 211(3):231.e1-9.
What is the optimal treatment for obese patients with advanced ovarian carcinoma?
Worley MJ, Davis M, Berhie SH, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS, Campos SM
Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma. Gynecol Oncol. 2014 Oct; 135(1):54-7.
Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma.
Zaino RJ, Brady WE, Todd W, Leslie K, Fischer EG, Horowitz NS, Mannel RS, Walker JL, Ivanovic M, Duska LR
Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study. Int J Gynecol Pathol. 2014 Nov; 33(6):543-53.
Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study.
Viswanathan AN, Lee LJ, Eswara JR, Horowitz NS, Konstantinopoulos PA, Mirabeau-Beale KL, Rose BS, von Keudell AG, Wo JY
Complications of pelvic radiation in patients treated for gynecologic malignancies. Cancer. 2014 Dec 15; 120(24):3870-83.
Complications of pelvic radiation in patients treated for gynecologic malignancies.
Smith HG, Horowitz N, Silverman NA, Henson DE, Chretien PB
Humoral immunity to herpes simplex viral-induced antigens in smokers. Cancer. 1976 Sep; 38(3):1155-62.
Humoral immunity to herpes simplex viral-induced antigens in smokers.
Rauh-Hain JA, Goodman A, Boruta DM, Schorge JO, Horowitz NS, del Carmen MG
Endometrial stromal sarcoma: a clinicopathologic study of 29 patients. J Reprod Med. 2014 Nov-Dec; 59(11-12):547-52.
Endometrial stromal sarcoma: a clinicopathologic study of 29 patients.
Owusu-Darko S, Rauh-Hain JA, Horowitz NS, Goodman A, Schorge JO, Del Carmen MG
Comparison of outcomes in patients with early-stage mucinous endometrial cancer and those with endometrioid endometrial cancer, with and without adjuvant therapy. J Reprod Med. 2014 Nov-Dec; 59(11-12):527-33.
Comparison of outcomes in patients with early-stage mucinous endometrial cancer and those with endometrioid endometrial cancer, with and without adjuvant therapy.
Aviki EM, Esselen KM, Barcia SM, Nucci MR, Horowitz NS, Feltmate CM, Berkowitz RS, Orgill DG, Viswanathan AN, Muto MG
Does plastic surgical consultation improve the outcome of patients undergoing radical vulvectomy for squamous cell carcinoma of the vulva? Gynecol Oncol. 2015 Apr; 137(1):60-5.
Does plastic surgical consultation improve the outcome of patients undergoing radical vulvectomy for squamous cell carcinoma of the vulva?
Melamed A, Katz Eriksen JL, Hinchcliff EM, Worley MJ, Berkowitz RS, Horowitz NS, Muto MG, Urman RD, Feltmate CM
Same-Day Discharge After Laparoscopic Hysterectomy for Endometrial Cancer. Ann Surg Oncol. 2016 Jan; 23(1):178-85.
Same-Day Discharge After Laparoscopic Hysterectomy for Endometrial Cancer.
Sun SY, Melamed A, Goldstein DP, Bernstein MR, Horowitz NS, Moron AF, Maestá I, Braga A, Berkowitz RS
Changing presentation of complete hydatidiform mole at the New England Trophoblastic Disease Center over the past three decades: does early diagnosis alter risk for gestational trophoblastic neoplasia? Gynecol Oncol. 2015 Jul; 138(1):46-9.
Changing presentation of complete hydatidiform mole at the New England Trophoblastic Disease Center over the past three decades: does early diagnosis alter risk for gestational trophoblastic neoplasia?
Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A
Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015 Feb 26; 160(5):977-989.
Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.
Hooley R, Lee C, Tocino I, Horowitz N, Carter D
Calcifications in axillary lymph nodes caused by fat necrosis. AJR Am J Roentgenol. 1996 Sep; 167(3):627-8.
Calcifications in axillary lymph nodes caused by fat necrosis.
Horowitz NS, Miller A, Rungruang B, Richard SD, Rodriguez N, Bookman MA, Hamilton CA, Krivak TC, Maxwell GL
Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol. 2015 Mar 10; 33(8):937-43.
Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182.
Howitt BE, Hanamornroongruang S, Lin DI, Conner JE, Schulte S, Horowitz N, Crum CP, Meserve EE
The American journal of surgical pathology
Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. Am J Surg Pathol. 2015 Mar; 39(3):287-93.
Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma.
Elias KM, Kang S, Liu X, Horowitz NS, Berkowitz RS, Frendl G
Anesthetic selection and disease-free survival following optimal primary cytoreductive surgery for stage III epithelial ovarian cancer. Ann Surg Oncol. 2015 Apr; 22(4):1341-8.
Anesthetic selection and disease-free survival following optimal primary cytoreductive surgery for stage III epithelial ovarian cancer.
Rauh-Hain JA, Foley OW, Winograd D, Andrade C, Clark RM, Vargas RJ, Hinchcliff EM, Esselen KM, Horowitz NS, del Carmen MG
Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer. Am J Obstet Gynecol. 2015 May; 212(5):600.e1-8.
Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.
Davis MR, Howitt BE, Quade BJ, Crum CP, Horowitz NS, Goldstein DP, Berkowitz RS
Epithelioid trophoblastic tumor: A single institution case series at the New England Trophoblastic Disease Center. Gynecol Oncol. 2015 Jun; 137(3):456-61.
Epithelioid trophoblastic tumor: A single institution case series at the New England Trophoblastic Disease Center.
Maestá I, Horowitz NS, Goldstein DP, Bernstein MR, Ramírez LA, Moulder J, Berkowitz RS
Response to chemotherapy in overweight/obese patients with low-risk gestational trophoblastic neoplasia. Int J Gynecol Cancer. 2015 May; 25(4):734-40.
Response to chemotherapy in overweight/obese patients with low-risk gestational trophoblastic neoplasia.
Maestá I, Berkowitz RS, Goldstein DP, Bernstein MR, Ramírez LA, Horowitz NS
Relationship between race and clinical characteristics, extent of disease, and response to chemotherapy in patients with low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2015 Jul; 138(1):50-4.
Relationship between race and clinical characteristics, extent of disease, and response to chemotherapy in patients with low-risk gestational trophoblastic neoplasia.
Matulonis U, Berlin S, Lee H, Whalen C, Obermayer E, Penson R, Liu J, Campos S, Krasner C, Horowitz N
Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol. 2015 Aug; 76(2):417-23.
Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies. Gynecol Oncol. 2015 Jul; 138(1):201-6.
Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies.
Horowitz N, Miller A, Rungruang B, Richard S, Rodriguez N, Bookman MA, Hamilton C, Krivak T, Maxwell GL
Reply to G.D. Aletti et al. J Clin Oncol. 2015 Oct 20; 33(30):3521-2.
Sun SY, Melamed A, Joseph NT, Gockley AA, Goldstein DP, Bernstein MR, Horowitz NS, Berkowitz RS
Clinical Presentation of Complete Hydatidiform Mole and Partial Hydatidiform Mole at a Regional Trophoblastic Disease Center in the United States Over the Past 2 Decades. Int J Gynecol Cancer. 2016 Feb; 26(2):367-70.
Clinical Presentation of Complete Hydatidiform Mole and Partial Hydatidiform Mole at a Regional Trophoblastic Disease Center in the United States Over the Past 2 Decades.
Optimal management of low-risk gestational trophoblastic neoplasia. Expert Rev Anticancer Ther. 2015; 15(11):1293-304.
Optimal management of low-risk gestational trophoblastic neoplasia.
Mahdi H, Gockley A, Esselen K, Marquard J, Nutter B, Yang B, Hinchcliff E, Horowitz N, Rose PG
Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer. Gynecol Oncol. 2015 Dec; 139(3):407-12.
Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer.
Erratum to: Anesthetic Selection and Disease-Free Survival Following Optimal Primary Cytoreductive Surgery for Stage III Epithelial Ovarian Cancer. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1611.
Erratum to: Anesthetic Selection and Disease-Free Survival Following Optimal Primary Cytoreductive Surgery for Stage III Epithelial Ovarian Cancer.
Erratum to: Anesthetic Selection and Disease-Free Survival Following Optimal Primary Cytoreductive Surgery for Stage III Epithelial Ovarian Cancer. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1606-7.
Gockley AA, Melamed A, Joseph NT, Clapp M, Sun SY, Goldstein DP, Horowitz NS, Berkowitz RS
The effect of adolescence and advanced maternal age on the incidence of complete and partial molar pregnancy. Gynecol Oncol. 2016 Mar; 140(3):470-3.
The effect of adolescence and advanced maternal age on the incidence of complete and partial molar pregnancy.
Howitt BE, Sun HH, Roemer MG, Kelley A, Chapuy B, Aviki E, Pak C, Connelly C, Gjini E, Shi Y, Lee L, Viswanathan A, Horowitz N, Neuberg D, Crum CP, Lindeman NL, Kuo F, Ligon AH, Freeman GJ, Hodi FS, Shipp MA, Rodig SJ
Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. JAMA Oncol. 2016 Apr; 2(4):518-22.
Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.
Viswanathan AN, Moughan J, Miller BE, Xiao Y, Jhingran A, Portelance L, Bosch WR, Matulonis UA, Horowitz NS, Mannel RS, Souhami L, Erickson BA, Winter KA, Small W, Gaffney DK
NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer. 2015 Jul 01; 121(13):2156-63.
NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer.
Gockley AA, Joseph NT, Melamed A, Sun SY, Goodwin B, Bernstein M, Goldstein DP, Berkowitz RS, Horowitz NS
Effect of race/ethnicity on clinical presentation and risk of gestational trophoblastic neoplasia in patients with complete and partial molar pregnancy at a tertiary care referral center. Am J Obstet Gynecol. 2016 09; 215(3):334.e1-6.
Effect of race/ethnicity on clinical presentation and risk of gestational trophoblastic neoplasia in patients with complete and partial molar pregnancy at a tertiary care referral center.
Davis M, Aviki E, Rauh-Hain JA, Worley M, Berkowitz R, Schorge J, Muto M, Clark Sisodia R, Horowitz N, Del Carmen M
Investigating the Impact of Body Mass Index on Intraperitoneal Chemotherapy Outcomes in Ovarian and Fallopian Tube Cancer. Int J Gynecol Cancer. 2016 07; 26(6):1033-40.
Investigating the Impact of Body Mass Index on Intraperitoneal Chemotherapy Outcomes in Ovarian and Fallopian Tube Cancer.
Berkowitz RS, Horowitz NS, Elias K, Goldstein DP
Gestational Trophoblastic Disease: Presentations from the XVIIIth World Congress on Gestational Trophoblastic Diseases. J Reprod Med. 2016 May-Jun; 61(5-6):185-6.
Gestational Trophoblastic Disease: Presentations from the XVIIIth World Congress on Gestational Trophoblastic Diseases.
Diver EJ, Horowitz NS, Goldstein DP, Bernstein M, Berkowitz RS, Growdon WB
Timing of Referral to the New England Trophoblastic Disease Center: Does Referral with Molar Pregnancy Versus Postmolar Gestational Trophoblastic Neoplasia Affect Outcomes? J Reprod Med. 2016 May-Jun; 61(5-6):187-91.
Timing of Referral to the New England Trophoblastic Disease Center: Does Referral with Molar Pregnancy Versus Postmolar Gestational Trophoblastic Neoplasia Affect Outcomes?
Sun SY, Goldstein DP, Bernstein MR, Horowitz NS, Mattar R, Maestá I, Braga A, Berkowitz RS
Maternal Near Miss According to World Health Organization Classification Among Women with a Hydatidiform Mole: Experience at the New England Trophoblastic Disease Center, 1994-2013. J Reprod Med. 2016 May-Jun; 61(5-6):210-4.
Maternal Near Miss According to World Health Organization Classification Among Women with a Hydatidiform Mole: Experience at the New England Trophoblastic Disease Center, 1994-2013.
Lee LJ, Howitt B, Catalano P, Tanaka C, Murphy R, Cimbak N, DeMaria R, Bu P, Crum C, Horowitz N, Matulonis U, Viswanathan AN
Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy. Gynecol Oncol. 2016 08; 142(2):293-8.
Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy.
Melamed A, Gockley AA, Joseph NT, Sun SY, Clapp MA, Goldstein DP, Berkowitz RS, Horowitz NS
Effect of race/ethnicity on risk of complete and partial molar pregnancy after adjustment for age. Gynecol Oncol. 2016 10; 143(1):73-76.
Effect of race/ethnicity on risk of complete and partial molar pregnancy after adjustment for age.
Watkins JC, Yang EJ, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS, Syngal S, Yurgelun MB, Chittenden A, Hornick JL, Crum CP, Sholl LM, Howitt BE
Universal Screening for Mismatch-Repair Deficiency in Endometrial Cancers to Identify Patients With Lynch Syndrome and Lynch-like Syndrome. Int J Gynecol Pathol. 2017 Mar; 36(2):115-127.
Universal Screening for Mismatch-Repair Deficiency in Endometrial Cancers to Identify Patients With Lynch Syndrome and Lynch-like Syndrome.
Sherman ME, Drapkin RI, Horowitz NS, Crum CP, Friedman S, Kwon JS, Levine DA, Shih IeM, Shoupe D, Swisher EM, Walker J, Trabert B, Greene MH, Samimi G, Temkin SM, Minasian LM
Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. Cancer Prev Res (Phila). 2016 Sep; 9(9):713-20.
Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.
Placental site trophoblastic tumors and epithelioid trophoblastic tumors: Biology, natural history, and treatment modalities. Gynecol Oncol. 2017 Jan; 144(1):208-214.
Placental site trophoblastic tumors and epithelioid trophoblastic tumors: Biology, natural history, and treatment modalities.
Watkins JC, Howitt BE, Horowitz NS, Ritterhouse LL, Dong F, MacConaill LE, Garcia E, Lindeman NI, Lee LJ, Berkowitz RS, Nucci MR, Crum CP
Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA. Mod Pathol. 2017 03; 30(3):448-458.
Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA.
Bigelow CA, Horowitz NS, Goodman A, Growdon WB, Del Carmen M, Kaimal AJ
Management and outcome of cervical cancer diagnosed in pregnancy. Am J Obstet Gynecol. 2017 03; 216(3):276.e1-276.e6.
Management and outcome of cervical cancer diagnosed in pregnancy.
Dorney KM, Growdon WB, Clemmer J, Rauh-Hain JA, Hall TR, Diver E, Boruta D, Del Carmen MG, Goodman A, Schorge JO, Horowitz N, Clark RM
Patient, treatment and discharge factors associated with hospital readmission within 30days after surgery for vulvar cancer. Gynecol Oncol. 2017 Jan; 144(1):136-139.
Patient, treatment and discharge factors associated with hospital readmission within 30days after surgery for vulvar cancer.
Rungruang BJ, Miller A, Krivak TC, Horowitz NS, Rodriguez N, Hamilton CA, Backes FJ, Carson LF, Friedlander M, Mutch DG, Goodheart MJ, Tewari KS, Wenham RM, Bookman MA, Maxwell GL, Richard SD
What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. Cancer. 2017 May 15; 123(6):985-993.
What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.
Killelea BK, Grube BJ, Philpotts L, Sowden M, Horowitz N, Lannin DR
Characteristics of multifocal and multicentric breast cancers detetected by preoperative MRI. J Clin Oncol. 2011 Sep 20; 29(27_suppl):67.
Characteristics of multifocal and multicentric breast cancers detetected by preoperative MRI.
Roche M, Matulonis U, Krasner C, Penson R, Horowitz N, Berkenblit A, Findley M, Lee J, Horick N, Seiden MV
Phase II trial of GM-CSF in women with asymptomatic müllerian cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5081.
Phase II trial of GM-CSF in women with asymptomatic müllerian cancer.
Lannin DR, Grube BJ, Killelea BK, Horowitz N, Harris L
Surgical and oncologic outcomes in patients with breast cancer undergoing tattooing prior to neoadjuvant chemotherapy. J Clin Oncol. 2011 Sep 20; 29(27_suppl):100.
Surgical and oncologic outcomes in patients with breast cancer undergoing tattooing prior to neoadjuvant chemotherapy.
Penson RT, Cannistra SA, Seiden MV, Krasner CN, Matulonis UA, Horowitz NS, Berlin S, Dizon DS, Lee H, Campos SM
Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5020.
Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors.
Esselen KM, Rodriguez N, Horowitz NS, Campos SM
Patterns of recurrence in advanced epithelial ovarian, fallopian tube, and peritoneal cancers treated with intraperitoneal chemotherapy. J Clin Oncol. 2011 May 20; 29(15_suppl):5072.
Patterns of recurrence in advanced epithelial ovarian, fallopian tube, and peritoneal cancers treated with intraperitoneal chemotherapy.
Viswanathan AN, Szymonifka J, Tanaka C, Berlin ST, Campos SM, Horowitz NS, Lee J, Whalen C, Matulonis U
The use of bevacizumab and concurrent radiation for recurrent gynecologic cancers. J Clin Oncol. 2011 May 20; 29(15_suppl):5101.
The use of bevacizumab and concurrent radiation for recurrent gynecologic cancers.
Lin LH, Maestá I, Braga A, Sun SY, Fushida K, Francisco RPV, Elias KM, Horowitz N, Goldstein DP, Berkowitz RS
Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: A retrospective multicenter cohort and literature review. Gynecol Oncol. 2017 Apr; 145(1):88-95.
Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: A retrospective multicenter cohort and literature review.
Duda DG, Cohen KS, Ancukiewicz M, di Tomaso E, Zhu AX, Penson RT, Horowitz NS, Batchelor TT, Willett CG, Jain RK
A comparative study of circulating endothelial cells (CECs) and circulating progenitor cells (CPCs) kinetics in four multidisciplinary phase II studies of antiangiogenic agents. J Clin Oncol. 2008 May 20; 26(15_suppl):3544.
A comparative study of circulating endothelial cells (CECs) and circulating progenitor cells (CPCs) kinetics in four multidisciplinary phase II studies of antiangiogenic agents.
Penson RT, Kornblith AB, Lee J, Roche M, Atkinson T, Gibson CD, Horowitz NS, Krag KJ, Krasner CN, Matulonis UA
Phase II study of carboplatin and paclitaxel in elderly women with newly diagnosed ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5590.
Phase II study of carboplatin and paclitaxel in elderly women with newly diagnosed ovarian, peritoneal, or fallopian tube cancer.
Horowitz NS, Penson RT, Campos SM, Lee J, Kendall DL, Krasner CN, Berlin ST, Roche M, Duska LR, Matulonis UA
Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5523.
Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
Sebastian S, Lee SI, Horowitz NS, Scott JA, Fischman AJ, Simeone JF, Fuller AF, Hahn PF
PET-CT vs. CT alone in ovarian cancer recurrence. Abdom Imaging. 2008 Jan-Feb; 33(1):112-8.
PET-CT vs. CT alone in ovarian cancer recurrence.
Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 01; 28(1):154-9.
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
Horowitz N, Pinto K, Mutch DG, Herzog TJ, Rader JS, Gibb R, Bocker-Edmonston T, Goodfellow PJ
Microsatellite instability, MLH1 promoter methylation, and loss of mismatch repair in endometrial cancer and concomitant atypical hyperplasia. Gynecol Oncol. 2002 Jul; 86(1):62-8.
Microsatellite instability, MLH1 promoter methylation, and loss of mismatch repair in endometrial cancer and concomitant atypical hyperplasia.
Meserve EEK, Mirkovic J, Conner JR, Yang E, Muto MG, Horowitz N, Strickland KC, Howitt BE, Crum CP
Frequency of "incidental" serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study. Gynecol Oncol. 2017 07; 146(1):69-73.
Frequency of "incidental" serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study.
Lee JH, Dubinsky T, Andreotti RF, Cardenes HR, Dejesus Allison SO, Gaffney DK, Glanc P, Horowitz NS, Jhingran A, Lee SI, Puthawala AA, Royal HD, Scoutt LM, Small W, Varia MA, Zelop CM
ACR appropriateness Criteria® pretreatment evaluation and follow-up of endometrial cancer of the uterus. Ultrasound Q. 2011 Jun; 27(2):139-45.
ACR appropriateness Criteria® pretreatment evaluation and follow-up of endometrial cancer of the uterus.
Wright JD, Powell MA, Horowitz NS, Huettner PC, White F, Herzog TJ
Placental site trophoblastic tumor presenting with a pneumothorax during pregnancy. Obstet Gynecol. 2002 Nov; 100(5 Pt 2):1141-4.
Placental site trophoblastic tumor presenting with a pneumothorax during pregnancy.
Nagymanyoki Z, Growdon WB, Sarno J, Callahan MJ, Parast MM, Fulop V, Mok SC, Horowitz N, Berkowitz RS
Vascularization and expression of angiogenic factors in partial and complete molar pregnancies. J Reprod Med. 2008 Aug; 53(8):589-94.
Vascularization and expression of angiogenic factors in partial and complete molar pregnancies.
Olawaiye A, Lee LM, Krasner C, Horowitz N
Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva. Gynecol Oncol. 2007 Sep; 106(3):628-30.
Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva.
Miller JC, Horowitz NS, Thrall JH, Lee SI
Evaluating adnexal lesions: which need follow-up? J Am Coll Radiol. 2007 Oct; 4(10):725-9.
Evaluating adnexal lesions: which need follow-up?
Management of gestational trophoblastic neoplasia. Semin Oncol. 2009 Apr; 36(2):181-9.
Management of gestational trophoblastic neoplasia.
Krasner CN, Roche M, Horowitz NS, Supko JG, Lee SI, Oliva E
Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis. N Engl J Med. 2006 Apr 13; 354(15):1615-25.
Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis.
Rauh-Hain JA, Rodriguez N, Growdon WB, Goodman AK, Boruta DM, Horowitz NS, del Carmen MG, Schorge JO
Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol. 2012 Mar; 19(3):959-65.
Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.
Worley MJ, Guseh SH, Rauh-Hain JA, Williams KA, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS
Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery? Gynecol Oncol. 2013 Apr; 129(1):69-73.
Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?
Rauh-Hain JA, del Carmen M, Horowitz NS, Alarcon IA, Ko E, Goodman AK, Olawaiye AB
Impact of bowel obstruction at the time of initial presentation in women with ovarian cancer. BJOG. 2010 Jan; 117(1):32-8.
Impact of bowel obstruction at the time of initial presentation in women with ovarian cancer.
Horowitz NS, Penson RT, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Cohen KS, Berlin S, Krasner CN, Moses MA, Jain RK
Clinical ovarian cancer and other gynecologic malignancies
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma. Clin Ovarian Cancer Other Gynecol Malig. 2011 Jun; 4(1):26-33.
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.
Horowitz NS, Cohn DE, Herzog TJ, Mutch DG, Rader JS, Bhalla S, Gibb RK
The significance of pneumatosis intestinalis or bowel perforation in patients with gynecologic malignancies. Gynecol Oncol. 2002 Jul; 86(1):79-84.
The significance of pneumatosis intestinalis or bowel perforation in patients with gynecologic malignancies.
Pepin K, Bregar A, Davis M, Melamed A, Hinchcliff E, Gockley A, Horowitz N, Del Carmen MG
Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery. Gynecol Oncol. 2017 12; 147(3):612-616.
Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery.
Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ
The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol Oncol. 2004 Jul; 94(1):67-73.
The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS, Hua J, Powell MA, Gibb RK, Mutch DG, Herzog TJ
Novel cytotoxic agents from an unexpected source: bile acids and ovarian tumor apoptosis. Gynecol Oncol. 2007 Nov; 107(2):344-9.
Novel cytotoxic agents from an unexpected source: bile acids and ovarian tumor apoptosis.
Campos SM, Berlin S, Matulonis UA, Muto MG, Pereira L, Mosquera MM, Horowitz N
Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function. J Psychosoc Oncol. 2012; 30(4):387-401.
Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function.
Maestá I, Nitecki R, Horowitz NS, Goldstein DP, de Freitas Segalla Moreira M, Elias KM, Berkowitz RS
Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience. Gynecol Oncol. 2018 01; 148(1):161-167.
Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience.
Haggerty AF, Hagemann A, Barnett M, Thornquist M, Neuhouser ML, Horowitz N, Colditz GA, Sarwer DB, Ko EM, Allison KC
A Randomized, Controlled, Multicenter Study of Technology-Based Weight Loss Interventions among Endometrial Cancer Survivors. Obesity (Silver Spring). 2017 11; 25 Suppl 2:S102-S108.
A Randomized, Controlled, Multicenter Study of Technology-Based Weight Loss Interventions among Endometrial Cancer Survivors.
del Carmen MG, Findley M, Muzikansky A, Roche M, Verrill CL, Horowitz N, Seiden MV
Demographic, risk factor, and knowledge differences between Latinas and non-Latinas referred to colposcopy. Gynecol Oncol. 2007 Jan; 104(1):70-6.
Demographic, risk factor, and knowledge differences between Latinas and non-Latinas referred to colposcopy.
Gius D, Funk MC, Chuang EY, Feng S, Huettner PC, Nguyen L, Bradbury CM, Mishra M, Gao S, Buttin BM, Cohn DE, Powell MA, Horowitz NS, Whitcomb BP, Rader JS
Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. Cancer Res. 2007 Aug 01; 67(15):7113-23.
Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates.
Horowitz NS, Peters WA, Smith MR, Drescher CW, Atwood M, Mate TP
Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma. Obstet Gynecol. 2002 Feb; 99(2):235-40.
Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma.
Rauh-Hain JA, Costaaggini I, Olawaiye AB, Growdon WB, Horowitz NS, del Carmen MG
European journal of gynaecological oncology
A comparison of outcome in patients with stage 1 clear cell and grade 3 endometrioid adenocarcinoma of the endometrium with and without adjuvant therapy. Eur J Gynaecol Oncol. 2010; 31(3):284-7.
A comparison of outcome in patients with stage 1 clear cell and grade 3 endometrioid adenocarcinoma of the endometrium with and without adjuvant therapy.
Management of adnexal masses in pregnancy. Clin Obstet Gynecol. 2011 Dec; 54(4):519-27.
Management of adnexal masses in pregnancy.
Hamilton CA, Miller A, Casablanca Y, Horowitz NS, Rungruang B, Krivak TC, Richard SD, Rodriguez N, Birrer MJ, Backes FJ, Geller MA, Quinn M, Goodheart MJ, Mutch DG, Kavanagh JJ, Maxwell GL, Bookman MA
Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecol Oncol. 2018 02; 148(2):275-280.
Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.
Horowitz NS, Larry Maxwell G, Miller A, Hamilton CA, Rungruang B, Rodriguez N, Richard SD, Krivak TC, Fowler JM, Mutch DG, Van Le L, Lee RB, Argenta P, Bender D, Tewari KS, Gershenson D, Java JJ, Bookman MA
Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol. 2018 01; 148(1):49-55.
Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.
Healing of vulvo-vaginal radionecrosis following revascularization. Gynecol Oncol. 2007 Jul; 106(1):262-4.
Healing of vulvo-vaginal radionecrosis following revascularization.
Horowitz N, Cohn DE, Luna JA, Winter TJ, Tamimi HK.
Intraoperative ultrasound in the management of ovarian germ cell tumors. Journal Gynecol Tech. 1999; 5:91-94.
Intraoperative ultrasound in the management of ovarian germ cell tumors
Dotan I, Yeshurun D, Hallak A, Horowitz N, Tiomny E, Reif S, Halpern Z, Rachmilewitz D
[Treatment of Crohn's disease with anti TNF alpha antibodies--the experience in the Tel Aviv Medical Center]. Harefuah. 2001 Apr; 140(4):289-93, 368.
[Treatment of Crohn's disease with anti TNF alpha antibodies--the experience in the Tel Aviv Medical Center].
Braga A, Campos V, Filho JR, Lin LH, Sun SY, de Souza CB, da Silva RCAF, Leal EAS, Silveira E, Maestá I, Madi JM, Uberti EH, Viggiano M, Elias KM, Horowitz N, Berkowitz RS
Is chemotherapy always necessary for patients with nonmetastatic gestational trophoblastic neoplasia with histopathological diagnosis of choriocarcinoma? Gynecol Oncol. 2018 02; 148(2):239-246.
Is chemotherapy always necessary for patients with nonmetastatic gestational trophoblastic neoplasia with histopathological diagnosis of choriocarcinoma?
Worley MJ, Elias KM, Horowitz NS, Quade BJ, Berkowitz RS
Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute. Gynecol Oncol. 2018 01; 148(1):5-11.
Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute.
Boyce EA, Costaggini I, Vitonis A, Feltmate C, Muto M, Berkowitz R, Cramer D, Horowitz NS
The epidemiology of ovarian granulosa cell tumors: a case-control study. Gynecol Oncol. 2009 Nov; 115(2):221-5.
The epidemiology of ovarian granulosa cell tumors: a case-control study.
Matulonis UA, Krag KJ, Krasner CN, Atkinson T, Horowitz NS, Lee H, Penson RT
Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors. Gynecol Oncol. 2009 Feb; 112(2):394-9.
Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.
Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009 Nov 20; 27(33):5601-6.
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
Rodriguez N, Rauh-Hain JA, Shoni M, Berkowitz RS, Muto MG, Feltmate C, Schorge JO, Del Carmen MG, Matulonis UA, Horowitz NS
Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2012 May; 125(2):362-6.
Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy.
Washington University Obstetrics and Gynecology Survival Guide. Editors: Wright JD, Wyatt S, Lin T.
Survival GYN/ONC. Washington University Obstetrics and Gynecology Survival Guide. Editors: Wright JD, Wyatt S, Lin T. 2003; 293-349.
Nitecki R, Davis M, Watkins JC, Wu YE, Vitonis AF, Muto MG, Berkowitz RS, Horowitz NS, Feltmate CM
Extramammary Paget Disease of the Vulva: A Case Series Examining Treatment, Recurrence, and Malignant Transformation. Int J Gynecol Cancer. 2018 03; 28(3):632-638.
Extramammary Paget Disease of the Vulva: A Case Series Examining Treatment, Recurrence, and Malignant Transformation.
Nitecki R, Berkowitz RS, Elias KM, Goldstein DP, Horowitz NS
Gestational Trophoblastic Disease Electronic Consults: What Do Patients and Physicians Want to Know? Int J Gynecol Cancer. 2018 05; 28(4):824-828.
Gestational Trophoblastic Disease Electronic Consults: What Do Patients and Physicians Want to Know?
Low-grade, low-stage endometrioid endometrial adenocarcinoma: a clinicopathologic analysis of 324 cases focusing on frequency and pattern of myoinvasion. Int J Gynecol Pathol. 2012 Jul; 31(4):337-43.
Low-grade, low-stage endometrioid endometrial adenocarcinoma: a clinicopathologic analysis of 324 cases focusing on frequency and pattern of myoinvasion.
Washington University Hematology and Oncology Consult Manual. Editors: Chanter M, Pillot G, Lin T
Gynecologic Oncology. Washington University Hematology and Oncology Consult Manual. Editors: Chanter M, Pillot G, Lin T. 2003; 197-203.
Effect of bismuth salts on systemic and mucosal immune responses to orally administered cholera toxin. Immunopharmacology. 1995 Nov; 31(1):31-41.
Effect of bismuth salts on systemic and mucosal immune responses to orally administered cholera toxin.
Growdon WB, Rauh-Hain JJ, Cordon A, Garrett L, Schorge JO, Goodman A, Boruta DM, Horowitz NS, del Carmen MG
Prognostic determinants in patients with stage I uterine papillary serous carcinoma: a 15-year multi-institutional review. Int J Gynecol Cancer. 2012 Mar; 22(3):417-24.
Prognostic determinants in patients with stage I uterine papillary serous carcinoma: a 15-year multi-institutional review.
Shah NT, Barroilhet L, Berkowitz RS, Goldstein DP, Horowitz N
A cost analysis of first-line chemotherapy for low-risk gestational trophoblastic neoplasia. J Reprod Med. 2012 May-Jun; 57(5-6):211-8.
A cost analysis of first-line chemotherapy for low-risk gestational trophoblastic neoplasia.
Horowitz NS, Olawaiye AB, Borger DR, Growdon WB, Krasner CN, Matulonis UA, Liu JF, Lee J, Brard L, Dizon DS
Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecol Oncol. 2012 Oct; 127(1):141-6.
Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva.
Primary peritoneal carcinoma presenting as adenocarcinoma on a Pap smear. A case report. J Reprod Med. 2002 Nov; 47(11):933-5.
Primary peritoneal carcinoma presenting as adenocarcinoma on a Pap smear. A case report.